The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition […]

The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition

How inhalers, injectables, and drug-device combinations are reshaping generic drug strategy — and what it takes to win. Abbreviated New

Track drug development pipelines and patent filings to surface passive candidates six to eighteen months before your competitors do. When

How drug companies, insurers, payers, and patients absorb billions in collateral damage that never appears on a litigation docket “The

The Number Everyone Gets Wrong Twenty years. Ask any pharma executive or patent attorney how long a drug patent lasts

The Mechanism Most Analysts Still Underestimate Every few years, a drug that has been off-patent for a decade reappears in

How to turn expiring blockbusters into budget wins — before your competitors do Patent cliffs don’t sneak up on anyone.

How hospital systems, PBMs, and self-insured employers can use IP intelligence to time generic switches and eliminate billions in avoidable